+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
M

Actively Recruiting

Researchers are evaluating mavorixafor, a drug being studied for people aged 12 and older who have congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders. These conditions cause low neutrophil levels and lead to recurrent or serious infections. The study aims to show if mavorixafor can improve clinical outcomes and increase neutrophil counts, while also assessing its safety and tolerability. Participants will continue their current treatment during the study, which may include therapies like granulocyte-colony stimulating factor G-CSF, immunoglobulin replacement, antibiotics, or no active treatment. They will be randomly assigned to receive either mavorixafor or a placebo orally once daily for up to 52 weeks. The study uses a quadruple-blind design to compare these groups in parallel. During the trial, participants will have regular assessments to monitor infection rates and severity, neutrophil counts, antibiotic use, oral ulcers, and fatigue levels using questionnaires. An independent committee will review infections to ensure accuracy. Safety and treatment effects will be followed throughout the 52-week treatment period. The total participation may last until the study ends in late 2027.

Age: 12Years +All GendersPhase 3
114 locations
C

Actively Recruiting

This trial is designed to evaluate the safety, tolerability, and effectiveness of the combination of nemtabrutinib plus venetoclax compared to venetoclax plus rituximab in adults with relapsed or refractory chronic lymphocytic leukemiasmall lymphocytic lymphoma RR CLLSLL. The study aims to confirm the dose of nemtabrutinib and assess progression-free survival as the primary outcome, using established criteria and independent review. Participants are assigned to one of two treatment groups. One group receives daily oral nemtabrutinib starting on the first day of cycle 1 and venetoclax starting on the first day of cycle 2, continuing up to two years or until disease progression or discontinuation. The other group receives daily oral venetoclax starting on cycle 1 day 1, plus intravenous rituximab infusion for six cycles. Each treatment cycle lasts four weeks. During the study, participants undergo regular monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations. Assessments include progression-free survival, minimal residual disease in bone marrow, overall survival, response rates, and duration of response. The study duration spans several years, with safety and efficacy monitored throughout and follow-up extending beyond treatment completion to gather comprehensive data on participant outcomes.

Age: 18Years +All GendersPhase 3
99 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of olverembatinib combined with chemotherapy compared to an investigators choice of tyrosine kinase inhibitor TKI combined with chemotherapy in adults newly diagnosed with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Ph ALL. This global, randomized, open-label Phase 3 study aims to provide important information about treatment options for this specific type of leukemia. Participants will receive either olverembatinib taken orally every other day along with chemotherapy, or a TKI chosen by the investigator taken orally once daily with chemotherapy. The study includes two groups one receiving the experimental olverembatinib combination and the other receiving the control treatment with investigator-selected TKI. Treatment cycles last 28 days, and the study follows participants through multiple cycles. During the study, participants will be monitored for their response to treatment by checking minimal residual disease negative complete remission rates during the first three cycles. Researchers will also assess event-free survival for up to 3 to 6 years, treatment-related side effects, drug levels in the blood, and quality of life related to leukemia. Safety assessments and other evaluations will continue through approximately two years of study participation, allowing for long-term monitoring of treatment effects and participant health.

Age: 18Years +All GendersPhase 3
90 locations
R

Actively Recruiting

Researchers are investigating whether adding intismeran autogene to pembrolizumab after surgery helps prevent cancer from returning in people with non-small cell lung cancer NSCLC whose tumors did not fully respond to treatment before surgery. This randomized phase 3 clinical trial compares pembrolizumab combined with intismeran autogene versus pembrolizumab with placebo in participants with resectable Stage II to IIIB NSCLC. The study focuses on individuals who have not achieved a complete pathological response after neoadjuvant therapy, aiming to improve disease-free survival. Participants receive neoadjuvant treatment consisting of pembrolizumab via intravenous infusion every 3 weeks for up to 4 cycles, combined with background chemotherapy chosen by the investigator. After surgery, the adjuvant treatment phase involves pembrolizumab given intravenously every 6 weeks for up to 7 cycles, plus either intismeran autogene or placebo administered by intramuscular injection every 3 weeks for up to 9 doses. The neoadjuvant phase lasts about 12 weeks, and the adjuvant phase extends up to approximately 42 weeks. During the study, participants will have regular assessments including monitoring for disease recurrence, survival, and quality of life using standardized questionnaires. Researchers will track adverse events and treatment tolerability throughout the trial, with follow-up lasting up to over 8 years to evaluate long-term outcomes. The main measurement is disease-free survival, with additional evaluations of overall survival, distant metastasis-free survival, and lung cancer-specific survival, along with patient-reported quality of life and safety data.

Age: 18Years +All GendersPhase 3
245 locations
C

Actively Recruiting

Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.

Age: 18Years +All GendersPhase 3
195 locations
M

Actively Recruiting

This research aims to provide continued treatment and evaluate the long-term safety of various study drugs for participants with advanced or metastatic cancer who have benefited from previous Daiichi Sankyo or Daiichi SankyoAstraZeneca-sponsored studies. It is an open-label, multicenter, phase 3 rollover study designed to offer ongoing access to these therapies and closely monitor participants health. Participants who choose to continue treatment with the drug T-DXd will maintain their last administered dose from the parent study unless a dose reduction is needed due to adverse events. The drug is given as an intravenous infusion every 21 days. Participants previously on comparator treatments may access T-DXd through standard care or other options. The study includes multiple sub-protocols covering different study drugs under a master rollover protocol. During the study, participants will be regularly monitored for adverse events, including serious and special interest events, from baseline until disease progression, loss of benefit, death, pregnancy, withdrawal, commercial access, physician decision, or study closure, up to about 2 years and 9 months. Safety assessments and adherence to contraception or reproductive guidelines will be required. The study spans from early 2024 through early 2028, with ongoing evaluations of treatment impact and participant health throughout.

Age: 18Years +All GendersPhase 3
34 locations
C

Actively Recruiting

Researchers are evaluating an experimental drug called odronextamab combined with lenalidomide for adults with relapsed or refractory Follicular Lymphoma FL or Marginal Zone Lymphoma MZL, which are subtypes of Non-Hodgkins Lymphoma NHL. This Phase 3 study includes two parts Part 1 to assess safety and dosing of the combination, and Part 2 to compare its effectiveness and safety against the current standard treatment of rituximab plus lenalidomide. The combination of odronextamab and lenalidomide is a first-in-human treatment being explored in this trial. In Part 1, participants receive odronextamab with lenalidomide to evaluate safety and determine dosing. In Part 2, participants are randomly assigned to receive either odronextamab plus lenalidomide or rituximab plus lenalidomide followed by lenalidomide alone, allowing comparison between the new combination and standard care. Both treatment combinations are administered according to the study protocol. Participants will be monitored for side effects, treatment tolerability, and disease progression through scheduled assessments including imaging scans and laboratory tests. Researchers will measure drug levels in the blood, immune responses against odronextamab, and quality of life impacts using questionnaires. Safety monitoring continues for up to two years, while efficacy outcomes such as progression-free survival and response duration are followed for up to five years, with ongoing evaluations throughout the study period.

Age: 18Years +All GendersPhase 3
171 locations
C

Actively Recruiting

Researchers are evaluating an experimental drug called odronextamab in adults with previously untreated follicular lymphoma, a type of non-Hodgkin lymphoma. The study consists of two parts Part 1 focuses on assessing the safety and tolerability of odronextamab alone, while Part 2 compares odronextamab to rituximab combined with chemotherapy, which is the current standard treatment. The research also explores side effects, drug levels in the blood, immune responses against the drug, and effects on quality of life and daily activities. Participants in Part 1 receive only odronextamab. In Part 2, participants are randomly assigned to one of two groups one group receives odronextamab followed by maintenance treatment with the same drug, and the other group receives rituximab combined with chemotherapy followed by rituximab maintenance. Chemotherapy options include combinations of cyclophosphamide, doxorubicin, vincristine, prednisone, and bendamustine, administered as described in the study protocol. Throughout the study, participants undergo regular assessments including imaging scans to measure disease, blood tests to monitor drug levels and immune response, and evaluations of physical function and quality of life. Researchers track adverse events and treatment responses up to five years. Safety and effectiveness are closely monitored, with key outcomes measured at intervals up to 30 months and beyond. The total participation time varies depending on treatment and follow-up schedules.

Age: 18Years +All GendersPhase 3
190 locations

1-10 of 18

1